Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2009/054970external-prioritypatent/WO2009113696A1/en
Application filed by Takeda PharmaceuticalfiledCriticalTakeda Pharmaceutical
Publication of TN2010000400A1publicationCriticalpatent/TN2010000400A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Plural Heterocyclic Compounds
(AREA)
Abstract
Provided is a crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole showing an X-ray powder diffraction pattern having characteristic peaks at interplanar spacings (d) of l0.06±0.2, 8.70±0.2, 6.57±0.2, 5.59±0.2 and 4.00±0.2 Angstroms. The present invention provides a stable antiulcer drug superior in the absorbability.
TNP2010000400A2009-03-092010-08-31Crystal of benzimidazole compound
TN2010000400A1
(en)
6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1h-pyrazo l-3-yl}-ethyl)-3h-1,3-benzothiazol-2-one as a tarp-gamma 8 dependent ampa receptor antagonist.
Process and methods for the preparation of optically active cis-2-hydroxymethyl-4-(cytosin-1´-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof